Business
Director's shareholding
Director's shareholding.
About this update from Genedrive Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5776O\n Genedrive PLC\n 11 October 2021\n \n \n \n \n genedrive plc\n \n \n (\"genedrive\", the \"Group\" or the \"Company\")\n \n \n \n \n \n Director's Shareholding\n \n \n \n \n \n \n London, UK\n \n \n \n - 11 October 2021:\n \n genedrive plc (LSE: GDR), the near patient molecular diagnostics company has been advised that as a result of an administrative error Dr. Ian Gilham, the Company's chairman, subscribed for 111,121 Open Offer Shares rather than 80,000 Open Offer Shares as was previously announced on 29 September 2021. As a result, Dr. Ian Gilham holds 614,295 Ordinary Shares in the Company, representing 0.67% of the Company's issued share capital. A corrected version of the PDMR notification form originally issued on 29 September 2021 is set out below, the only material change is to the number of Open Offer Shares subscribed for by Dr. Ian Gilham.\n \n \n \n \n \n Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 10 September 2021.\n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n genedrive plc\n \n \n \n \n +44 (0) 161 989 0245\n \n \n \n \n \n \n David Budd (Chief Executive Officer)\n \n \n Matthew Fowler (Chief Financial Officer) \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Peel Hunt\n \n \n LLP - Nominated Adviser & Joint Broker\n \n \n \n \n \n \n \n +44 (0) 20 7148 8900\n \n \n \n \n \n \n James Steel (Investment Banking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n finnCap Ltd - Joint Broker\n \n \n \n \n \n \n \n +44 (0) 20 7220 0500\n \n \n \n \n \n \n Geoff Nash / Kate Bannatyne (Corporate Finance)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Walbrook PR - Financial PR & IR Adviser\n \n \n \n \n +44 (0) 20 7933 8780\n \n \n \n \n \n \n Paul McManus / Anna Dunphy \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n...